This clinical trial is focused on studying a condition called Antineutrophil Cytoplasmic Antibody Associated Vasculitis (AAV), which can lead to a serious kidney problem known as rapidly progressive glomerulonephritis (RPGN). The study is testing a new treatment called ALE.F02, which is given through an intravenous infusion, meaning it is administered directly into the bloodstream. The purpose of the study is to evaluate the safety and tolerability of ALE.F02 in patients with RPGN due to AAV.

Participants in the study will receive either ALE.F02 or a placebo. The study will last for several weeks, during which participants will have regular check-ups to monitor their health and the effects of the treatment. The study aims to see if ALE.F02 can help protect the kidneys and improve kidney function in patients with this condition. Other medications that may be used in the study include Rituximab, a type of monoclonal antibody, and Cyclophosphamide, a chemical used in some treatments. These medications are also given through intravenous administration.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The study will also look at how ALE.F02 affects kidney function over time, including changes in protein levels in the urine and overall kidney health. The goal is to find out if ALE.F02 can be a safe and effective treatment option for people with RPGN due to AAV, potentially offering a new way to manage this challenging condition.